E
Eugene Braunwald
Researcher at Brigham and Women's Hospital
Publications - 1758
Citations - 278949
Eugene Braunwald is an academic researcher from Brigham and Women's Hospital. The author has contributed to research in topics: Myocardial infarction & TIMI. The author has an hindex of 230, co-authored 1711 publications receiving 264576 citations. Previous affiliations of Eugene Braunwald include Boston University & University of California, San Francisco.
Papers
More filters
Chronic coronary artery disease
TL;DR: This article aims to integrate the information obtained from a history, physical examination, and a stress test to diagnose and stratify the risk of patients with chronic coronary artery disease, and apply evidencebased management strategies to improve survival in patients with Chronic Coronary Artery Disease.
Journal ArticleDOI
Impaired coronary blood flow in nonculprit arteries in the setting of acute myocardial infarction
C M Gibson,K. Ryan,Sabina A. Murphy,Rebecca Mesley,Susan J. Marble,Robert P. Giugliano,Christopher P. Cannon,Elliott M. Antman,Eugene Braunwald +8 more
TL;DR: Acute MI slows flow globally, and slower global flow is associated with adverse outcomes, especially in patients who died and patients who survived.
Journal ArticleDOI
ACE inhibitors--a cornerstone of the treatment of heart failure.
TL;DR: For many years digitalis and diuretic agents have been the cornerstones of pharmacologic treatment for patients with heart failure, but a potential therapeutic role for vasodilators was first suggested in 2012.
Journal ArticleDOI
Evaluation of the Glycometabolic Effects of Ranolazine in Patients With and Without Diabetes Mellitus in the MERLIN-TIMI 36 Randomized Controlled Trial
David A. Morrow,Benjamin M. Scirica,Bernard R. Chaitman,Darren K. McGuire,Sabina A. Murphy,Ewa Karwatowska-Prokopczuk,Carolyn H. McCabe,Eugene Braunwald +7 more
TL;DR: Ranolazine significantly improved HbA1c and recurrent ischemia in patients with diabetes mellitus and reduced the incidence of increased Hb a1c in those without evidence of previous hyperglycemia.
Journal ArticleDOI
Genetics and the clinical response to warfarin and edoxaban: findings from the randomised, double-blind ENGAGE AF-TIMI 48 trial
Jessica L. Mega,Joseph R. Walker,Christian T. Ruff,Alexander G. Vandell,Francesco Nordio,Naveen Deenadayalu,Sabina A. Murphy,James Lee,Michele Mercuri,Robert P. Giugliano,Elliott M. Antman,Eugene Braunwald,Marc S. Sabatine +12 more
TL;DR: After 90 days, the reduction in bleeding risk with edoxaban versus warfarin was similarly beneficial across genotypes, and treatment with Edoxaban reduced bleeding more so in sensitive and highly sensitive responders than in normal responders.